|
|
 |
|
Viewing report
|
|
|
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More Drugs on the Market, More Targets in the Pipeline
Datamonitor, Oct 2006, Pages: 430
Cancer treatment continues to embrace the inclusion of molecular targeted therapies (MTT) into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.
Scope of this title:
-Seven major pharmaceutical market sales forecasts from 2005 to 2015 for approved molecular targeted therapies and key pipeline candidates
-Review of the current targeted therapies market, including profiles, product-specific assumptions and events over the forecasted period
-Research and analysis of the targeted therapies pipeline with in-depth clinical and commercial assessment of Phase III candidates, plus expert opinion
-Examination of product pipeline by phase, mode of action, indication, drug class and developer, plus two commercial impact case studies
Highlights of this title:
In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR of 12.9%. This growth will be driven mainly by Genentech/Roches Rituxan, Herceptin and Avastin as well as Novartis Gleevec, all of which have already reached blockbuster status.
274 different pipeline MTTs have been identified. The introduction of current late-phase candidates, including the pre-registered agents Tykerb (lapatinib; GlaxoSmithKline) and Zolinza (vorinostat; Merck), will further increase the markets total value by $3.8 billion, enabling the targeted therapies market to reach $29.1 billion in 2015.
The rise in cost of cancer treatment is unsustainable with growing pharmacoeconomic pressures challenging healthcare payers globally. To counter these hurdles, developers must become more effective at communicating the value of their products. To this end, a comprehensive understanding of the targeted therapies market and pipeline is critical.
Reasons to order your copy:
-Acquire a detailed appreciation and impartial perspective of the targeted cancer therapies market as a whole
-Consider and react to the specific events influencing the future potential of marketed and pipeline targeted therapies
-Gain an insight into the emerging clinical, developmental and commercial challenges and opportunities facing key developmental and marketed MTT drugs
Customers who bought this item also bought
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Prospects for the Phase III Bapineuzumab Trial
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
Stakeholder Insight: Renal Cancer - Targeted therapies rapidly take hold of market
Cancer Therapies - Global Strategic Business Report
Pipeline Insight: Molecular Targeted Cancer Therapies: Can Anything Else Revolutionize the Market?
Antibody drug conjugates for cancer treatment: Clinical Trial Pipeline
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Cancer Drug Resistance
Innovations and Trends in Clinical Trials - Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
Hemostats Clinical Trial Analysis
Tumour Markers Clinical Trial Analysis
|
|
|
|
